St. Jude Medical, Inc. v. Commissioner of Internal Revenue

34 F.3d 1394, 74 A.F.T.R.2d (RIA) 6166, 1994 U.S. App. LEXIS 24468
CourtCourt of Appeals for the Eighth Circuit
DecidedSeptember 9, 1994
Docket93-2642
StatusPublished
Cited by18 cases

This text of 34 F.3d 1394 (St. Jude Medical, Inc. v. Commissioner of Internal Revenue) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
St. Jude Medical, Inc. v. Commissioner of Internal Revenue, 34 F.3d 1394, 74 A.F.T.R.2d (RIA) 6166, 1994 U.S. App. LEXIS 24468 (8th Cir. 1994).

Opinion

MAGILL, Circuit Judge.

In this appeal, we are asked to decide the effect of Treasury Regulation § 1.861-8 (as amended in 1977) on computations requiring application of the intercompany pricing rules of the domestic international sales corporation (DISC) statute, I.R.C. §§ 991-997. St. Jude Medical, Inc. (St. Jude) challenges the United States Tax Court’s decision that the Commissioner of the Internal Revenue (the Commissioner) correctly assessed a tax deficiency against it for tax years 1981,1982, and 1983. The tax court found that, in DISC combined taxable income (CTI) computations, St. Jude improperly allocated research and development (R & D) expenditures 1 related to (1) its attempt to develop an insulin pump and a cardiac pacemaker and (2) its successful heart valve sales. We affirm the tax court’s determination as to St. Jude’s allocation of heart-valve-related R & D expenditures. We reverse the tax court’s holding that St. Jude improperly failed to allocate the insulin pump and pacemaker R&D expenditures to its heart valve gross export receipts and remand to the tax court for further proceedings consistent with this opinion. 2

I. BACKGROUND

St. Jude is a domestic corporation that designs, manufactures, and sells medical products. A calendar year taxpayer, St. Jude incurred R&D expenses related to three medical products: an insulin pump, a cardiac pacemaker, and an artificial heart valve. The heart valve research resulted in successful sales both in the United States and in foreign markets. In contrast, the insulin pump and cardiac pacemaker R&D efforts were abandoned, never resulting in a product or in any sales receipts. During the years in question, all gross export receipts resulted from heart valve sales.

To facilitate its export transactions, St. Jude incorporated St. Jude International Sales Corporation (International), a wholly-owned subsidiary, and qualified it as a DISC. *1396 St. Jude was required by the DISC statute’s intercompany pricing rules, see I.R.C. § 994, to calculate the DISC’S commission and hence its taxable income through specific methods, one of which was the CTI method. In calculating CTI, St. Jude failed to allocate a portion of the unsuccessful insulin pump and cardiac pacemaker R & D expenditures to International and St. Jude’s gross export receipts as required by § 1.861-8. St. Jude contended that § 1.861-8 was invalid as it applied to those allocations. Further, St. Jude failed to allocate its artificial heart valve R & D expenditures to its gross export receipts in DISC CTI computations, contending that § 223 of the Economic Recovery Tax Act of 1981 (ERTA), Pub.L. No. 97-34, 95 Stat. 172, 249, exempted it from doing so.

In 1988, the Commissioner notified St. Jude of a tax deficiency for calendar years 1979 to 1983. St. Jude petitioned the tax court for redetermination of the deficiencies, first resolving with the Commissioner all issues other than the proper allocation of R & D expenditures for calendar years 1981 through 1983. No factual issues were in dispute. The tax court held that St. Jude improperly failed to allocate its insulin pump and pacemaker R & D expenditures to its heart valve gross export receipts. The tax court also held that St. Jude improperly apportioned its heart-valve-related R & D expenditures in its CTI computations. St. Jude timely appealed.

II. DISCUSSION

We are presented with two legal issues in this appeal: (1) whether § 1.861 — 8(e)(3) could validly be applied to require International and St. Jude to include in their CTI computation the expenses related to the unsuccessful insulin pump and pacemaker R & D and (2) whether § 223 of ERTA, suspending § 1.861-8, exempted St. Jude and International from including any domestically performed R & D expenditures — specifically, the artificial heart valve R & D expenditures — in their CTI computation during the time ERTA was in effect (the ERTA Moratorium). Our review of legal questions is de novo. Estate of Robertson v. Commissioner, 15 F.3d 779, 781 (8th Cir.1994). We hold that § 1.861 — 8(e)(3) is invalid as applied to DISC CTI computations. We further hold that § 223 of ERTA did not permit St. Jude and International to avoid allocating and apportioning any of their heart-valve-related R & D expenditures to their heart valve gross export receipts in their CTI computation. We review the relevant law and analyze these issues in turn.

A. The Statutory Framework

1. The DISC Legislation

In 1971, Congress enacted the DISC statute intending to provide tax incentives to domestic firms, thereby increasing exports. At that time, Congress believed that domestic firms exporting goods in a foreign market were at a disadvantage as compared to foreign subsidiaries of domestic corporations. H.R.Rep. No. 533, 92d Cong., 1st Sess. 57, 58 (1971) [hereinafter H.R.Rep. No. 533], reprinted in 1971 U.S.C.C.A.N. 1825, 1872. Prior to the enactment of the DISC legislation, domestic companies directly marketing their goods in a foreign market were taxed on “their foreign earnings at the full U.S. corporate income tax rate regardless of whether [the] earnings [were] kept abroad or repatriated.” Id.

The DISC statute permitted a domestic corporation to set up a DISC, a subsidiary incorporated under “the laws of any State.” I.R.C. § 992(a)(1). A corporation could elect to be treated as a DISC if it satisfied several specific requirements. See id. Most significantly, “95 percent or more of the gross receipts [of a DISC must] consist of qualified export receipts.” Id. § 992(a)(1)(A). Once qualified as a DISC, such a corporation’s profits were generally not subject to taxation. Id. § 991. However, the DISC’S shareholders were taxed on a portion of the DISC’S profits in the form of a deemed dividend. See id. § 995. The remainder of DISC profit was not taxable until it was distributed to the shareholder, typically upon the dissolution or disqualification of the DISC. See e.g., id. § 995(b)(2). The shareholder’s yearly deemed dividend attributable to qualified export receipts was taxed as foreign source income, I.R.C. § 862(a)(2), *1397 thus qualifying for a corresponding foreign tax credit, id. §§ 901, 904.

The incentive created by Congress in the DISC legislation allowed the domestic corporation, the shareholder of the DISC, to defer from U.S. taxation a significant portion of the DISC profits. Congress also set up DISC intercompany pricing rules abrogating arms length pricing as the basis for sales or exchanges between the domestic parent corporation and the DISC. See H.R.Rep. No. 533 at 59, reprinted in 1971 U.S.C.C.A.N. at 1873. The intercompany pricing rules were intended to

avoid the complexities of the [arms length] pricing rules in the case of sales by a domestic parent corporation ...

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
34 F.3d 1394, 74 A.F.T.R.2d (RIA) 6166, 1994 U.S. App. LEXIS 24468, Counsel Stack Legal Research, https://law.counselstack.com/opinion/st-jude-medical-inc-v-commissioner-of-internal-revenue-ca8-1994.